Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Mirum Pharmaceuticals, Inc.
Bear Case (25th pct.)
-95.0% vs price
Base Case (Median)
-93.8% vs price
Bull Case (75th pct.)
-92.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $3.08 | -96.3% | High (40%) |
| EV/EBITDA | $7.24 | -91.3% | Medium (20%) |
Based on 2 out of 7 methods, MIRM appears overvalued at the current price of $82.93. The base case fair value of $5.16 implies 93.8% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.